Literature DB >> 24418994

Improved long-term survival in multiple myeloma up to the age of 80 years.

S Y Kristinsson1, W F Anderson2, O Landgren3.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24418994     DOI: 10.1038/leu.2014.23

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Recent major improvement in long-term survival of younger patients with multiple myeloma.

Authors:  Hermann Brenner; Adam Gondos; Dianne Pulte
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

Review 4.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

5.  Treating myeloma: the future is already here!

Authors:  Ola Landgren; Neha Korde
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

6.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study.

Authors:  Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

7.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

8.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Paul W Dickman; Asa Rangert Derolf; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

View more
  61 in total

1.  Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Anders Wahlin; Sham Mailankody; Cecilie Blimark; Malin Hultcrantz; Anna Porwit; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Haematologica       Date:  2015-12-17       Impact factor: 9.941

2.  Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy.

Authors:  Yong Tang; Ye-Hua Yu; Yi-Yun Yao; Li-Fang Zou; Hong-Ju Dou; Lei Wang; Qi Zhu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-27       Impact factor: 0.900

Review 3.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

4.  The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma.

Authors:  Mark A Fiala; Nicole C Foley; Sonja Zweegman; Ravi Vij; Tanya M Wildes
Journal:  J Geriatr Oncol       Date:  2020-03-10       Impact factor: 3.599

5.  Health-related quality of life in patients with multiple myeloma--does it matter?

Authors:  Ann Kristin Kvam; Anders Waage
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

6.  Early mortality in multiple myeloma.

Authors:  L J Costa; W I Gonsalves; S K Kumar
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

7.  ESRD due to Multiple Myeloma in the United States, 2001-2010.

Authors:  Scott Reule; Donal J Sexton; Craig A Solid; Shu-Cheng Chen; Robert N Foley
Journal:  J Am Soc Nephrol       Date:  2015-10-29       Impact factor: 10.121

Review 8.  Multiple myeloma epidemiology and survival: A unique malignancy.

Authors:  Dickran Kazandjian
Journal:  Semin Oncol       Date:  2016-11-10       Impact factor: 4.929

Review 9.  Update on second primary malignancies in multiple myeloma: a focused review.

Authors:  O Landgren; S Mailankody
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

10.  Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

Authors:  Cecilie Blimark; Erik Holmberg; Ulf-Henrik Mellqvist; Ola Landgren; Magnus Björkholm; Malin Hultcrantz; Christian Kjellander; Ingemar Turesson; Sigurdur Y Kristinsson
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.